1. Simonneau, G, Montani, D, Celermajer, DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019; 53: 1801913.
Google Scholar | Crossref2. Thenappan, T, Ormiston, ML, Ryan, JJ, et al. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ 2018; 360: j5492.
Google Scholar | Medline3. Hirani, N, Brunner, NW, Kapasi, A, et al. Canadian Cardiovascular Society/Canadian Thoracic Society position statement on pulmonary hypertension. Can J Cardiol 2020; 36: 977–992.
Google Scholar | Crossref | Medline4. International PPH Consortium , Lane, KB, Machado, RD, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 2000; 26: 81–84.
Google Scholar | Crossref | Medline5. Castaño, JAT, Hernández-Gonzalez, I, Gallego, N, et al. Customized massive parallel sequencing panel for diagnosis of pulmonary arterial hypertension. Genes 2020; 11: 1158.
Google Scholar | Crossref6. Harbaum, L, Rhodes, CJ, Otero-Núñez, P, et al. The application of “omics” to pulmonary arterial hypertension. Br J Pharmacol 2021; 178: 108–120.
Google Scholar | Crossref | Medline7. Kan, M, Shumyatcher, M, Himes, BE. Using omics approaches to understand pulmonary diseases. Respir Res 2017; 18: 149.
Google Scholar | Crossref | Medline8. Smejkal, GB. The promise of gel-based proteomics. Expert Opin Drug Discov 2006; 1: 7–10.
Google Scholar | Crossref | Medline9. Meleady, P, Abdul Rahman, R, Henry, M, et al. Proteomic analysis of pancreatic ductal adenocarcinoma. Expert Rev Proteomics 2020; 17: 453–467.
Google Scholar | Crossref | Medline10. Merchant, M, Weinberger, SR. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 2000; 21: 1164–1177.
Google Scholar | Crossref | Medline11. Sandberg, A, Branca, RM, Lehtiö, J, et al. Quantitative accuracy in mass spectrometry based proteomics of complex samples: the impact of labeling and precursor interference. J Proteomics 2014; 96: 133–144.
Google Scholar | Crossref | Medline12. Zelniker, T, Uhlmann, L, Spaich, S, et al. Novel biomarkers for risk stratification in pulmonary arterial hypertension. ERJ Open Res 2015; 1: 00008-2015.
Google Scholar | Crossref | Medline13. Foris, V, Kovacs, G, Tscherner, M, et al. Biomarkers in pulmonary hypertension: what do we know? Chest 2013; 144: 274–283.
Google Scholar | Crossref | Medline14. Warwick, G, Thomas, PS, Yates, DH. Biomarkers in pulmonary hypertension. Eur Respir J 2008; 32: 503–512.
Google Scholar | Crossref | Medline15. Ramjug, S, Weatherald, J, Sahay, S, et al. ERS International Congress, Madrid, 2019: highlights from the Pulmonary Vascular Diseases Assembly. ERJ Open Res 2020; 6: 00304-2020.
Google Scholar | Crossref16. Damico, R, Kolb, TM, Valera, L, et al. Serum endostatin is a genetically determined predictor of survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 2015; 191: 208–218.
Google Scholar | Crossref | Medline17. Hoffmann, J, Marsh, LM, Pieper, M, et al. Compartment-specific expression of collagens and their processing enzymes in intrapulmonary arteries of IPAH patients. Am J Physiol Lung Cell Mol Physiol 2015; 308: L1002–L1013.
Google Scholar | Crossref | Medline18. Abdul-Salam, VB, Paul, GA, Ali, JO, et al. Identification of plasma protein biomarkers associated with idiopathic pulmonary arterial hypertension. Proteomics 2006; 6: 2286–2294.
Google Scholar | Crossref | Medline19. Yu, M, Wang, XX, Zhang, FR, et al. Proteomic analysis of the serum in patients with idiopathic pulmonary arterial hypertension. J Zhejiang Univ Sci B 2007; 8: 221–227.
Google Scholar | Crossref | Medline20. Rice, LM, Mantero, JC, Stratton, EA, et al. Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther 2018; 20: 185.
Google Scholar | Crossref | Medline21. Sandqvist, A, Schneede, J, Kylhammar, D, et al. Plasma L-arginine levels distinguish pulmonary arterial hypertension from left ventricular systolic dysfunction. Heart Vessels 2018; 33: 255–263.
Google Scholar | Crossref | Medline22. Zhang, J, Zhang, Y, Li, N, et al. Potential diagnostic biomarkers in serum of idiopathic pulmonary arterial hypertension. Respir Med 2009; 103: 1801–1806.
Google Scholar | Crossref | Medline23. Yuan, C, Chen, HX, Hou, HT, et al. Protein biomarkers and risk scores in pulmonary arterial hypertension associated with ventricular septal defect: integration of multi-omics and validation. Am J Physiol Lung Cell Mol Physiol 2020; 319: L810–L822.
Google Scholar | Crossref | Medline24. Rhodes, CJ, Wharton, J, Ghataorhe, P, et al. Plasma proteome analysis in patients with pulmonary arterial hypertension: an observational cohort study. Lancet Respir Med 2017; 5: 717–726.
Google Scholar | Crossref | Medline25. Sweatt, AJ, Hedlin, HK, Balasubramanian, V, et al. Discovery of distinct immune phenotypes using machine learning in pulmonary arterial hypertension. Circ Res 2019; 124: 904–919.
Google Scholar | Crossref | Medline26. Galiè, N, Humbert, M, Vachiery, JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37: 67–119.
Google Scholar | Crossref | Medline27. Kikuchi, N, Satoh, K, Satoh, T, et al. Diagnostic and prognostic significance of serum levels of SeP (Selenoprotein P) in patients with pulmonary hypertension. Arterioscler Thromb Vasc Biol 2019; 39: 2553–2562.
Google Scholar | Crossref | Medline28. Tamura, Y, Ono, T, Kuwana, M, et al. Human pentraxin 3 (PTX3) as a novel biomarker for the diagnosis of pulmonary arterial hypertension. PLoS ONE 2012; 7: e45834.
Google Scholar | Crossref29. Wang, KY, Lee, MF, Ho, HC, et al. Serum Caveolin-1 as a novel biomarker in idiopathic pulmonary artery hypertension. Biomed Res Int 2015; 2015: 173970.
Google Scholar | Medline30. Di Benedetto, P, Guggino, G, Manzi, G, et al. Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension. Arthritis Res Ther 2020; 22: 127.
Google Scholar | Crossref | Medline31. McGoon, MD, Benza, RL, Escribano-Subias, P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013; 62: D51–D59.
Google Scholar | Crossref | Medline32. Galiè, N, Channick, RN, Frantz, RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J 2019; 53: 1801889.
Google Scholar | Crossref | Medline33. Benza, RL, Miller, DP, Gomberg-Maitland, M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122: 164–172.
Google Scholar | Crossref | Medline34. Benza, RL, Gomberg-Maitland, M, Elliott, CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. Chest 2019; 156: 323–337.
Google Scholar | Crossref | Medline35. Boucly, A, Weatherald, J, Savale, L, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J 2017; 50: 1700889.
Google Scholar | Crossref | Medline36. Hoeper, MM, Kramer, T, Pan, Z, et al. Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model. Eur Respir J 2017; 50: 1700740.
Google Scholar | Crossref | Medline37. Kylhammar, D, Kjellström, B, Hjalmarsson, C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J 2018; 39: 4175–4181.
Google Scholar | Crossref | Medline38. Ghantasala, S, Gollapalli, K, Epari, S, et al. Glioma tumor proteomics: clinically useful protein biomarkers and future perspectives. Expert Rev Proteomics 2020; 17: 221–232.
Google Scholar | Crossref | Medline39. Régent, A, Ly, KH, Lofek, S, et al. Proteomic analysis of vascular smooth muscle cells in physiological condition and in pulmonary arterial hypertension: toward contractile versus synthetic phenotypes. Proteomics 2016; 16: 2637–2649.
Google Scholar | Crossref | Medline40. Xu, W, Comhair, SAA, Chen, R, et al. Integrative proteomics and phosphoproteomics in pulmonary arterial hypertension. Sci Rep 2019; 9: 18623.
Google Scholar | Crossref | Medline41. Faber, MJ, Dalinghaus, M, Lankhuizen, IM, et al. Time dependent changes in cytoplasmic proteins of the right ventricle during prolonged pressure overload. J Mol Cell Cardiol 2007; 43: 197–209.
Google Scholar | Crossref | Medline42. James, J, Valuparampil Varghese, M, Vasilyev, M, et al. Complex III inhibition-induced pulmonary hypertension affects the mitochondrial proteomic landscape. Int J Mol Sci 2020; 21: 5683.
Google Scholar | Crossref43. Prisco, SZ, Rose, L, Potus, F, et al. Excess protein O-GlcNAcylation links metabolic derangements to right ventricular dysfunction in pulmonary arterial hypertension. Int J Mol Sci 2020; 21: 7278.
Google Scholar | Crossref44. Hołda, MK, Stachowicz, A, Suski, M, et al. Myocardial proteomic profile in pulmonary arterial hypertension. Sci Rep 2020; 10: 14351.
Google Scholar | Crossref | Medline45. Shields, KJ, Verdelis, K, Passineau, MJ, et al. Three-dimensional micro computed tomography analysis of the lung vasculature and differential adipose proteomics in the Sugen/hypoxia rat model of pulmonary arterial hypertension. Pulm Circ 2016; 6: 586–596.
Google Scholar | SAGE Journals46. Malenfant, S, Potus, F, Fournier, F, et al. Skeletal muscle proteomic signature and metabolic impairment in pulmonary hypertension. J Mol Med 2015; 93: 573–584.
Google Scholar | Crossref | Medline47. Abdul-Salam, VB, Wharton, J, Cupitt, J, et al. Proteomic analysis of lung tissues from patients with pulmonary arterial hypertension. Circulation 2010; 122: 2058–2067.
Google Scholar | Crossref | Medline48. Abdul-Salam, VB, Russomanno, G, Chien-Nien, C, et al. CLIC4/Arf6 pathway. Circ Res 2019; 124: 52–65.
Google Scholar | Crossref | Medline49. Hemnes, AR, Luther, JM, Rhodes, CJ, et al. Human PAH is characterized by a pattern of lipid-related insulin resistance. JCI Insight 2019; 4: e123611.
Google Scholar | Crossref | Medline50. Zhang, X, Hou, HT, Wang, J, et al. Plasma proteomic study in pulmonary arterial hypertension associated with congenital heart diseases. Sci Rep 2016; 6: 36541.
Google Scholar | Crossref | Medline51. Aulak, KS, Al Abdi, S, Li, L, et al. Disease-specific platelet signaling defects in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2021; 320: L739–L749.